Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defects.

Science translational medicine - 7 Jan 2026

Pennetzdorfer Nina, Naik Vidula, Demirdjian Sally, Hendricks Matthew R, Jamieson Cooper S, Perry Jason K, VanderVeen Laurie A, Yant Stephen R, Dvory-Sobol Hadas, Ogbuagu Onyema, Gupta Samir K, Margot Nicolas A, Callebaut Christian

Abstract excerpt

Lenacapavir (LEN) is a long-acting HIV-1 capsid inhibitor that binds to the HIV-1 capsid protein with picomolar antiviral activity, disrupting its function and inhibiting viral replication. Here, we identified capsid mutations in samples from individuals treated with LEN across two clinical trials that were considered potential LEN resistance-associated mutations. The gag encoding regions of clinical isolates...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetamides
Share to Capsid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capsid Proteins

Share to Drug Resistance, Viral

Share to Indazoles

Share to Models, Molecular

Share to Virus Replication

Source

Identifiers

PMID: 41499523
DOI: 10.1126/scitranslmed.aea0947

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defects.PMID 41499523Read ↗

Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavirSemantic proximity Read ↗

Recurrent and novel evolutionary pathways drive in vitro HIV-1 lenacapavir resistance with diverse phenotypic consequences.Semantic proximity Read ↗

Structural and mechanistic bases for resistance of the M66I capsid variant to lenacapavir.Semantic proximity Read ↗

Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.Semantic proximity Read ↗

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.Semantic proximity Read ↗

Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy With Lenacapavir-containing RegimenSemantic proximity Read ↗

Phenotypic Characterization of Replication‐Impaired Lenacapavir‐Resistant HIV Clinical IsolatesSemantic proximity Read ↗

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 YearsSemantic proximity Read ↗

HIV-1 capsid variability: viral exploitation and evasion of capsid-binding moleculesSemantic proximity Read ↗

Rapid HIV-1 genotyping assay for the detection of capsid mutations.Semantic proximity Read ↗

Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes.Semantic proximity Read ↗

Structural and Mechanistic Bases for Resistance of the M66I Capsid Variant to LenacapavirSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.